Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q01973

UPID:
ROR1_HUMAN

ALTERNATIVE NAMES:
Neurotrophic tyrosine kinase, receptor-related 1

ALTERNATIVE UPACC:
Q01973; Q5VVX6; Q66K77; Q92776

BACKGROUND:
The protein ROR1, with minimal kinase activity, is unlikely to function as a tyrosine kinase in vivo. It binds to ligand WNT5A, triggering NFkB signaling and potentially inhibiting WNT3A-mediated pathways. Essential for the connection between spiral ganglion neurons and auditory hair cells, ROR1 plays a pivotal role in hearing.

THERAPEUTIC SIGNIFICANCE:
Given ROR1's critical function in hearing and its association with deafness, autosomal recessive, 108, exploring its mechanisms offers promising avenues for developing treatments for sensorineural hearing impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.